Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
$33.98+0.05 (+0.15%)
Close on Nov 13, 2026Market cap $2.24BP/E 6.3Yield –
Lakefront Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
For fiscal 2025 it was 26.5%, against -68.3% the year before. The highest annual figure on record is 44.2% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26.5% | +94.9 |
| FY2024 | Dec 31, 2024 | -68.3% | −31.5 |
| FY2023 | Dec 31, 2023 | -36.8% | +17.5 |
| FY2022 | Dec 31, 2022 | -54.3% | +18.9 |
| FY2021 | Dec 31, 2021 | -73.2% | −35.8 |
| FY2020 | Dec 31, 2020 | -37.4% | −81.5 |
| FY2019 | Dec 31, 2019 | 44.2% | +61.1 |
| FY2018 | Dec 31, 2018 | -16.9% | +53.8 |
| FY2017 | Dec 31, 2017 | -70.7% | −61.8 |
| FY2016 | Dec 31, 2016 | -8.9% | +217.2 |
| FY2015 | Dec 31, 2015 | -226.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | -33.4% | +47.0 |
| Q2 FY2020 | Jun 30, 2020 | -88.5% | – |
| Q2 FY2019 | Jun 30, 2019 | -75.5% | – |
| Q2 FY2018 | Jun 30, 2018 | -67.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -80.5% | – |
See a number that looks wrong?